Wright Medical said it will appeal the FDA’s decision not to approve the Augment bone graft as an alternative to autograft in hind foot and ankle fusion procedures. The “not approvable” letter cited agency concerns that the Augment clinical trial population was “predominantly low-risk and therefore may not have warranted the use of either autograft or Augment Bone Graft,” Wright said.
Renowned orthopaedic surgeon, Michael Alexiades, MD, appointed as newest member of Intellijoint Surgical’s Scientific Advisory Board
February 21, 2019
February 20, 2019
February 12, 2019